Noel S Weiss

Dr. Noel S Weiss


Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2004 in Cancer
Verified
Journal Article
Open access
PDF file
CCChen Chu
Chen Chu
SLS. Kay Lewis
S. Kay Lewis
LVLynda Voigt
Lynda Voigt
AFAnnette Fitzpatrick
Annette Fitzpatrick
SPStephen R. Plymate
Stephen R. Plymate
NWNoel S Weiss
Noel S Weiss
BACKGROUND There have been several epidemiologic studies investigating the association between circulating levels of insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and insulin in relation to the risk of prostate carcinoma, with conflicting results. To examine this issue further, the authors conducted a nested case–control study within the Cardiovascular Health Study cohort. METHODS In men who were diagnosed with prostate carcinoma (cases) between 1990 and 1999 (n = 174), the levels of IGF-I, IGFBP-3, and insulin were measured on blood samples that were obtained 1–9 years prior to diagnosis (mean, 3.4 years). Similar measurements were made on 174 male participants without prostate carcinoma (controls) who were matched to cases based on the year blood was drawn, survival until the date of diagnosis, race, and age. RESULTS Relative to the men with IGF-I levels in the first (lowest) quartile of the distribution, the risk of prostate carcinoma for men in the second, third, and fourth (upper) quartiles were 0.77 (95% confidence interval [95% CI], 0.43–1.38), 0.73 (95% CI, 0.41–1.30), and 0.67 (95% CI, 0.37–1.25), respectively. The results were influenced little by adjustment for levels of IGFBP-3 or, instead, by evaluating the molar IGF-I/IGFBP-3 ratio. An analysis that was restricted to men who had plasma prostate-specific antigen levels < 4 ng/mL at the time of the blood draw yielded similar results. The corresponding relative risks for IGFBP-3 were 0.91 (95% CI, 0.49–1.68), 0.47 (95% CI, 0.25–0.94), and 0.65 (95% CI, 0.35–1.20), respectively. The distribution of serum insulin levels in cases and controls were nearly identical. CONCLUSIONS The IGF-I level was not associated positively with the risk of prostate carcinoma; however, an increase in the IGFBP-3 level was associated with a modest decrease in risk. Cancer 2005. © 2004 American Cancer Society.

1 May 2013 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
CDChyke A. Doubeni
Chyke A. Doubeni
SWSheila Weinmann
Sheila Weinmann
KAKenneth F. Adams
Kenneth F. Adams
AKAruna Kamineni
Aruna Kamineni
DBDiana S. Buist
Diana S. Buist
VDVincent P. Doria-Rose
Vincent P. Doria-Rose

15 June 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
PLPeter J. Leary
Peter J. Leary
EHEdward Hess
Edward Hess
ABAnna E. Barón
Anna E. Barón
KBKelley R. Branch
Kelley R. Branch
GCGaurav Choudhary
Gaurav Choudhary
TLTim Lahm
Tim Lahm

1 March 2014 in European Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
NWNoel S Weiss
Noel S Weiss

1 May 2011 in Epidemiology
Verified
Journal Article
Closed access
NWNoel S Weiss
Noel S Weiss

18 March 2003 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
NLNajib Lamharzi
Najib Lamharzi
MJMelissa M. Johnson
Melissa M. Johnson
GGGary Goodman
Gary Goodman
RERuth Etzioni
Ruth Etzioni
NWNoel S Weiss
Noel S Weiss
CCChen Chu
Chen Chu
In the prostate, the enzyme encoded by the SRD5A2 gene (5α‐reductase) converts testosterone to dihydrotestosterone, a potent androgen that has been hypothesized to play a role in the genesis of prostate cancer. Several polymorphisms have been identified in the SRD5A2 gene, including a valine‐to‐leucine substitution (V89L) at codon 89, a variable number of TA dinucleotide repeats and a missense substitution at codon 49 resulting in an amino acid substitution of alanine with threonine (A49T). To investigate the influence of these polymorphisms on prostate cancer risk, we conducted a case‐control study nested within the Beta‐Carotene and Retinol Efficacy Trial. Genotypes were determined by PCR‐based capillary electrophoresis using genomic DNA isolated from 300 cases and 300 controls matched on the basis of race, age at enrollment (within 5 years), enrollment study center and year of randomization. There was no association between V89L genotypes and prostate cancer risk. The age‐ and race‐adjusted odds ratio (OR) associated with the VL and LL genotypes were 1.06 (95% confidence interval (CI) = 0.75‐1.49) and 0.99 (95% CI = 0.57‐1.73), respectively, as compared to the VV genotype. The age‐ and race‐adjusted odds ratio for men having 1 TA(9) or TA(18) allele was 0.98 (95% CI = 0.64‐1.48) when compared to men without TA repeats. The corresponding odds ratio for men without the TA(0) alleles was 0.68 (95% CI = 0.21‐2.19). The age‐ and race‐adjusted odds ratio associated with having at least 1 T allele at codon 49 was 1.11 (95% CI = 0.58‐2.11), as compared to the AA genotype. Our results do not support the hypothesis that the V89L and A49T polymorphisms in the SRD5A2 gene are related to the risk of prostate cancer, but are compatible with the suggestion from earlier studies that men who are homozygous for the TA(9) or (18) alleles and men who have the TA(9)/TA(18) genotype are at a modestly reduced risk.